200 related articles for article (PubMed ID: 21494122)
1. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.
Piché N; Leblond FA; Sidéris L; Pichette V; Drolet P; Fortier LP; Mitchell A; Dubé P
Ann Surg; 2011 Jul; 254(1):138-44. PubMed ID: 21494122
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model.
Badrudin D; Perrault-Mercier C; Bouchard-Fortier A; Hubert J; Leblond FA; Sideris L; Dubé P
Surg Oncol; 2016 Dec; 25(4):435-440. PubMed ID: 27251757
[TBL] [Abstract][Full Text] [Related]
3. Reply to Letter: "Rationale for Heating Oxaliplatin for the Intraperitoneal Treatment of Peritoneal Carcinomatosis".
Sideris L; Drolet P; Mitchell A; Dubé P
Ann Surg; 2016 Apr; 263(4):e60-1. PubMed ID: 26636241
[No Abstract] [Full Text] [Related]
4. About the Rationale for Heating Oxaliplatin During HIPEC.
Ortega-Deballon P; Facy O; Rat P; Chauffert B
Ann Surg; 2016 Apr; 263(4):e60. PubMed ID: 24169194
[No Abstract] [Full Text] [Related]
5. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
[TBL] [Abstract][Full Text] [Related]
6. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.
Facy O; Al Samman S; Magnin G; Ghiringhelli F; Ladoire S; Chauffert B; Rat P; Ortega-Deballon P
Ann Surg; 2012 Dec; 256(6):1084-8. PubMed ID: 22634898
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the administration of systemic 5-FU in combination with heated intraperitonal oxaliplatin.
Badrudin D; Sideris L; Leblond FA; Pichette V; Cloutier AS; Drolet P; Dubé P
Surg Oncol; 2018 Jun; 27(2):275-279. PubMed ID: 29937182
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
9. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.
Mas-Fuster MI; Ramon-Lopez A; Lacueva J; Compañ A; Más-Serrano P; Nalda-Molina R
Cancer Chemother Pharmacol; 2017 Mar; 79(3):621-627. PubMed ID: 28168311
[TBL] [Abstract][Full Text] [Related]
10. A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin.
Miailhe G; Arfi A; Mirshahi M; Eveno C; Pocard M; Touboul C
J Visc Surg; 2018 Jun; 155(3):183-189. PubMed ID: 29108718
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
[TBL] [Abstract][Full Text] [Related]
12. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Elias D; Pocard M; Goere D
Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
[TBL] [Abstract][Full Text] [Related]
14. [Intraperitoneal chemotherapy with oxaliplatin after complete cytoreduction for peritoneal carcinomatosis from colorectal carcinoma: preliminary experience].
Mura G; Framarini M; Milandri C; Rosetti P; Vagliasindi A; Solfrini G; Mazza P; Verdecchia GM
Suppl Tumori; 2005; 4(3):S111-2. PubMed ID: 16437938
[TBL] [Abstract][Full Text] [Related]
15. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
[TBL] [Abstract][Full Text] [Related]
16. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
[TBL] [Abstract][Full Text] [Related]
17. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
[TBL] [Abstract][Full Text] [Related]
18. Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model.
Badrudin D; Sideris L; Perrault-Mercier C; Hubert J; Leblond FA; Dubé P
J Surg Oncol; 2018 May; 117(6):1318-1322. PubMed ID: 29355970
[TBL] [Abstract][Full Text] [Related]
19. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.
Pérez-Ruixo C; Peris JE; Escudero-Ortiz V; Bretcha-Boix P; Farré-Alegre J; Pérez-Ruixo JJ; Valenzuela B
Cancer Chemother Pharmacol; 2014 May; 73(5):1009-20. PubMed ID: 24663502
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin for chemotherapeutic treatment and prevention of experimental peritoneal carcinomatosis in rats comparing the intraperitoneal and intravenous application mode.
Hribaschek A; Meyer F; Ridwelski K; Kuester D; Lippert H
Eur Surg Res; 2010; 44(2):74-81. PubMed ID: 20051689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
